NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

RVMD

Revolution Medicines Inc

Jul 11 • 04:00PM ET

38.02

Dollar change -0.48
Percentage change -1.25	%

Healthcare • Biotechnology • USA • NASD

Peers: AMGN GILD VRTX BMY MRNA PFE REGN ILMN BIIB EXEL

| Held by: VTI VB VXF VBK XBI IBB VTWO SCHA IWR SCHM

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-4.00	Insider Own	13.09%	Shs Outstand	186.26M	Perf Week	0.40%
Market Cap	7.08B	Forward P/E	-	EPS next Y	-4.94	Insider Trans	-0.23%	Shs Float	161.88M	Perf Month	-9.43%
Enterprise Value	5.11B	PEG	-	EPS next Q	-1.12	Inst Own	93.57%	Short Float	9.95%	Perf Quarter	8.26%
Income	-697.51M	P/S	-	EPS this Y	-31.40%	Inst Trans	-0.44%	Short Ratio	6.95	Perf Half Y	-14.23%
Sales	0.00M	P/B	3.41	EPS next Y	-4.97%	ROA	-32.64%	Short Interest	16.10M	Perf YTD	-13.08%
Book/sh	11.16	P/C	3.37	EPS next 5Y	-6.64%	ROE	-36.68%	52W High	62.40 -39.07%	Perf Year	-13.43%
Cash/sh	11.29	P/FCF	-	EPS past 3/5Y	-11.66% -27.80%	ROIC	-31.71%	52W Low	29.17 30.34%	Perf 3Y	62.97%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	3.30% 3.86%	Perf 5Y	29.06%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-6.30%	Oper. Margin	-	ATR (14)	1.49	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	13.46	Sales Y/Y TTM	-100.00%	Profit Margin	-	RSI (14)	47.35	Recom	1.08
Dividend Gr. 3/5Y	- -	Current Ratio	13.46	EPS Q/Q	-61.08%	SMA20	-1.24%	Beta	1.16	Target Price	72.91
Payout	-	Debt/Eq	0.06	Sales Q/Q	-	SMA50	-3.32%	Rel Volume	0.60	Prev Close	38.50
Employees	534	LT Debt/Eq	0.06	Earnings	May 07 AMC	SMA200	-11.71%	Avg Volume	2.32M	Price	38.02
IPO	Feb 13, 2020	Option/Short	Yes / Yes	EPS/Sales Surpr.	-3.60% -	Trades		Volume	1,400,149	Change	-1.25%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-16-24	Reiterated	Needham	Buy	$46 → $62
Jul-12-24	Initiated	Barclays	Overweight	$52
Jul-08-24	Initiated	Jefferies	Buy	$63
Apr-12-24	Reiterated	Needham	Buy	$36 → $46
Apr-10-24	Upgrade	Raymond James	Outperform → Strong Buy	$36 → $48
Mar-11-24	Initiated	Piper Sandler	Overweight	$43
Jan-05-24	Upgrade	BofA Securities	Neutral → Buy	$31 → $34
Jan-04-24	Initiated	Wedbush	Outperform	$41
Nov-16-23	Initiated	Raymond James	Outperform	$30
Feb-28-23	Upgrade	JP Morgan	Neutral → Overweight	$32 → $38
Dec-14-22	Initiated	Needham	Buy	$31
Oct-21-22	Initiated	Oppenheimer	Outperform	$30
May-20-22	Initiated	BofA Securities	Neutral	$24
Mar-01-22	Upgrade	Stifel	Hold → Buy	$36 → $26
Sep-23-21	Initiated	Stifel	Hold	$34
Aug-12-21	Downgrade	Goldman	Buy → Neutral	$49 → $27
May-18-21	Initiated	Goldman	Buy	$49
May-21-20	Initiated	H.C. Wainwright	Buy	$55
Mar-09-20	Initiated	JP Morgan	Neutral	$32
Mar-09-20	Initiated	Guggenheim	Buy	$50

Show Previous Ratings

Jul-09-25 08:00AM	Revolution Medicines and Iambic Announce Technology and Research Collaboration Using Iambic's AI Discovery Tools to Pursue New Drug Candidates (GlobeNewswire) +5.71%
12:55AM	Revolution Medicines' Daraxonrasib Granted FDA Breakthrough Therapy Designation for Pancreatic Cancer with KRAS G12 Mutations (Insider Monkey)
Jul-06-25 04:00AM	Revolution Medicines, Summit Therapeutics Partner on RAS Inhibitor/Ivonescimab Combinations for Solid Tumors (Insider Monkey)
Jul-02-25 03:20AM	Oppenheimer Reaffirms Outperform on Revolution Medicines, Cites PDAC and NSCLC Trial Progress (Insider Monkey)
Jun-30-25 08:00AM	Revolution Medicines and Summit Therapeutics Enter Into Clinical Collaboration to Evaluate Combinations of Three RAS(ON) Inhibitors With Ivonescimab in RAS Mutant Tumors (Business Wire)
05:23AM	Loading…
Jun-25-25 05:23AM	Revolution Medicines partners Royalty Pharma on $2bn funding (Pharmaceutical Technology)
Jun-24-25 07:00AM	Revolution Medicines Enters Into $2 Billion Flexible Funding Agreement with Royalty Pharma to Support Global Development and Commercialization of RAS(ON) Inhibitor Portfolio for Patients with RAS-Addicted Cancers (GlobeNewswire)
Jun-23-25 09:00AM	Revolution Medicines Announces FDA Breakthrough Therapy Designation for Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer with KRAS G12 Mutations (GlobeNewswire)
May-14-25 08:00AM	Revolution Medicines Announces First Patient Dosed in Phase 3 Clinical Trial Evaluating Daraxonrasib in Previously Treated Patients with RAS Mutant Non-Small Cell Lung Cancer (GlobeNewswire)
May-07-25 06:59PM	Revolution medicines outlines 2025 focus on RAS(ON) inhibitors in key cancer trials (Seeking Alpha) +11.29%
06:58PM	Revolution Medicines, Inc. (RVMD) Q1 2025 Earnings Call Transcript (Seeking Alpha)
04:02PM	Revolution Medicines Reports First Quarter 2025 Financial Results and Update on Corporate Progress (GlobeNewswire)
Apr-30-25 04:05PM	Revolution Medicines to Report Financial Results for First Quarter 2025 After Market Close on May 7, 2025 (GlobeNewswire)
Apr-27-25 12:05PM	Revolution Medicines Presents Initial Data from Zoldonrasib (RMC-9805) Study in Patients with KRAS G12D Mutant Non-Small Cell Lung Cancer at the 2025 AACR Annual Meeting (GlobeNewswire)
Apr-11-25 12:30AM	Harbor Health Care ETF Q4 2024 Commentary (Seeking Alpha) +6.09%
05:00AM	Loading…
Apr-09-25 05:00AM	Barbara Weber, M.D., Elected to ITM Supervisory Board (GlobeNewswire) +12.82%
Apr-08-25 06:29AM	Revolution Medicines: Overpriced RAS-Addicted Cancers Maven (Seeking Alpha)
Apr-01-25 04:05PM	Revolution Medicines to Deliver Multiple Presentations at the 2025 American Association for Cancer Research (AACR) Annual Meeting (GlobeNewswire)
Mar-31-25 04:43PM	Revolution Medicines (RVMD): The Best Debt Free Mid Cap Stock to Buy Now (Insider Monkey) -5.33%
04:05PM	Revolution Medicines to Participate in April 2025 Investor Conferences (GlobeNewswire)
Mar-30-25 04:12PM	Is Revolution Medicines (RVMD) the Best Mid Cap Biotech Stock to Buy? (Insider Monkey)
Feb-26-25 04:02PM	Revolution Medicines Reports Fourth Quarter and Full Year 2024 Financial Results and Update on Corporate Progress (GlobeNewswire)
Feb-24-25 04:05PM	Revolution Medicines to Participate in March 2025 Investor Conferences (GlobeNewswire)
Feb-19-25 04:05PM	Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2024 After Market Close on February 26, 2025 (GlobeNewswire)
Jan-29-25 04:05PM	Revolution Medicines to Participate in the Guggenheim Securities SMID Cap Biotech Conference (GlobeNewswire) +5.25%
Jan-06-25 04:05PM	Revolution Medicines to Present at 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-05-24 04:05PM	Revolution Medicines Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire)
Dec-04-24 06:51AM	Revolution Medicines price target raised to $87 from $82 at Guggenheim (TipRanks)
Dec-03-24 10:38PM	Revolution Medicines Announces Pricing of Upsized $750.0 Million Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire) -6.89%
Dec-02-24 04:31PM	Revolution Medicines Announces Commencement of Public Offering of Common Stock (GlobeNewswire) -10.46%
07:30AM	Loading…
07:30AM	Revolution Medicines Provides Clinical Updates from its RAS(ON) Inhibitor Portfolio (GlobeNewswire)
Nov-27-24 04:05PM	Revolution Medicines to Host RAS(ON) Inhibitor Clinical Update Webcast on December 2, 2024 (GlobeNewswire)
Nov-06-24 04:02PM	Revolution Medicines Reports Third Quarter 2024 Financial Results and Update on Corporate Progress (GlobeNewswire)
Nov-05-24 09:00AM	Revolution Medicines to Participate in Upcoming Investor Conferences (GlobeNewswire)
Oct-30-24 04:05PM	Revolution Medicines to Report Financial Results for Third Quarter 2024 After Market Close on November 6, 2024 (GlobeNewswire) +5.94%
Oct-25-24 04:15AM	Revolution Medicines Presents Initial Data from RMC-9805 Monotherapy Study in Patients with Advanced Pancreatic Ductal Adenocarcinoma (GlobeNewswire)
Oct-23-24 06:00AM	Revolution Medicines Presents Updated Data from RMC-6236 Monotherapy Study in Patients with Advanced Pancreatic Ductal Adenocarcinoma (GlobeNewswire)
Oct-21-24 04:05PM	Revolution Medicines Announces First Patient Dosed in Phase 3 Study Evaluating RMC-6236 in Previously Treated Patients with Metastatic Pancreatic Ductal Adenocarcinoma (GlobeNewswire) -5.31%
Oct-07-24 09:00AM	Revolution Medicines to Deliver Multiple Presentations at the 2024 AACR-NCI-EORTC Symposium and Host Investor Webcast (GlobeNewswire)
Aug-07-24 04:05PM	Revolution Medicines Reports Second Quarter 2024 Financial Results and Update on Corporate Progress (GlobeNewswire)
Jul-31-24 04:05PM	Revolution Medicines to Report Financial Results for Second Quarter 2024 After Market Close on August 7, 2024 (GlobeNewswire)
Jul-11-24 12:00PM	Revolution Medicines Announces Publication Demonstrating Robust Anti-Tumor Activity of RAS(ON) Inhibitors in Preclinical Models of Refractory KRAS-Mutated Non-Small Cell Lung Cancer (GlobeNewswire)
Jul-10-24 05:58AM	Revolution Medicines (RVMD) Moves 11.0% Higher: Will This Strength Last? (Zacks)
Jul-08-24 04:05PM	Revolution Medicines to Provide Update on RMC-6236 Pancreatic Ductal Adenocarcinoma Clinical Program on July 15, 2024 (GlobeNewswire) +5.46% +10.97%
Jun-08-24 09:00AM	The 7 Most Undervalued Under-$50 Stocks to Buy in June 2024 (InvestorPlace)
Jun-05-24 04:05PM	Revolution Medicines to Participate in Goldman Sachs 45th Annual Global Healthcare Conference (GlobeNewswire)
Jun-04-24 06:00AM	The 3 Most Undervalued Biotech Stocks to Buy in June 2024 (InvestorPlace)
May-09-24 03:41PM	Revolution Medicines, Inc. (NASDAQ:RVMD) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-08-24 09:58PM	RVMD Stock Earnings: Revolution Medicines Beats EPS for Q1 2024 (InvestorPlace)
04:02PM	Revolution Medicines Reports First Quarter 2024 Financial Results and Update on Corporate Progress (GlobeNewswire)
May-01-24 04:05PM	Revolution Medicines to Report Financial Results for First Quarter 2024 After Market Close on May 8, 2024 (GlobeNewswire)
Apr-09-24 03:34PM	Revolution Medicines Announces Publication on the Discovery of and Translational Research for RMC-6236, an Investigational RAS(ON) Multi-Selective Tri-Complex Inhibitor Designed to Block Full Spectrum of Oncogenic RAS(ON) Proteins (GlobeNewswire)
Apr-08-24 11:36AM	Revolution Medicines Announces Publications on the Discovery and Preclinical Profile of Representative of a New Class of RAS(ON) Multi-Selective Inhibitors Designed to Block Full Spectrum of Oncogenic RAS(ON) Proteins (GlobeNewswire)
Apr-04-24 04:05PM	Revolution Medicines to Participate in Upcoming Investor Conferences (GlobeNewswire)
Mar-28-24 04:05PM	Revolution Medicines to Deliver Multiple Presentations at the Upcoming American Association for Cancer Research Annual Meeting 2024 (GlobeNewswire)
Feb-26-24 05:20PM	Revolution Medicines, Inc. (RVMD) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
04:05PM	Revolution Medicines Reports Fourth Quarter and Full Year 2023 Financial Results and Update on Corporate Progress (GlobeNewswire)
Feb-20-24 04:05PM	Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2023 After Market Close on February 26, 2024 (GlobeNewswire)
Feb-01-24 04:05PM	Revolution Medicines to Participate in Upcoming Investor Conferences (GlobeNewswire)
Jan-17-24 09:55AM	Wall Street Analysts See a 27.5% Upside in Revolution Medicines, Inc. (RVMD): Can the Stock Really Move This High? (Zacks)
Jan-04-24 07:00AM	Revolution Medicines to Present at 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Nov-09-23 09:10AM	Revolution Medicines Completes Acquisition of EQRx (GlobeNewswire) -5.48%
Nov-08-23 11:30AM	Revolution Medicines and EQRx Stockholders Approve EQRx Acquisition (GlobeNewswire)
Nov-07-23 10:14AM	Revolution Medicines, Inc. (NASDAQ:RVMD) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-06-23 05:50PM	Revolution Medicines, Inc. (RVMD) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
04:55PM	Revolution Medicines Inc (RVMD) Reports Q3 2023 Financial Results and Corporate Progress (GuruFocus.com)
04:05PM	Revolution Medicines Reports Third Quarter 2023 Financial Results and Update on Corporate Progress (GlobeNewswire)
Nov-01-23 07:00AM	Leading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Revolution Medicines Stockholders Vote FOR Proposed Acquisition of EQRx, Inc. (GlobeNewswire)
Oct-31-23 04:15PM	Revolution Medicines to Report Financial Results for Third Quarter 2023 After Market Close on November 6, 2023 (GlobeNewswire) +7.90%
Oct-23-23 04:06PM	Revolution Crashes 34% On A Flop In Pancreatic Cancer Treatment. But There's A Silver Lining. (Investor's Business Daily) -34.38% +14.52%
01:48PM	Rebel's Edge - October 20: $TGH, $RVMD, and Astros VS Rangers (TheStreet.com)
12:04PM	Why Revolution Medicines Stock Is Crashing Today (Motley Fool)
10:07AM	Revolution Medicines Crashes 39% On Lackluster Test Results In Cancer Treatment (Investor's Business Daily)
Oct-22-23 02:30AM	Revolution Medicines Presents Promising Clinical Activity and Safety Data from Phase 1/1b Trial of RMC-6236 (GlobeNewswire)
Oct-19-23 07:02AM	Insider Sell: COO Margaret Horn Sells 25,000 Shares of Revolution Medicines Inc (GuruFocus.com)
Oct-16-23 03:19PM	Revolution Medicines Stock Joins Elite Club With RS Ratings Over 90 (Investor's Business Daily) +14.08%
09:45AM	Revolution Medicines, Inc. (RVMD) Soars 23.6%: Is Further Upside Left in the Stock? (Zacks)
Oct-13-23 02:54PM	Why Shares of Revolution Medicines Were Popping on Friday (Motley Fool) +23.60%
11:50AM	Revolution Medicines Presents Encouraging Clinical Data for RMC-6236 and RMC-6291 at 2023 Triple Meeting (GlobeNewswire)
Oct-04-23 04:05PM	Revolution Medicines to Present New Clinical Data at Major Oncology Conferences and Host Investor Webcast (GlobeNewswire)
Sep-20-23 07:01AM	Insider Sell: COO Margaret Horn Sells 7,514 Shares of Revolution Medicines Inc (RVMD) (GuruFocus.com)
Sep-19-23 07:00AM	Revolution Medicines Doses First Patient in Phase 1/1b Clinical Trial of RMC-9805, an Oral, Covalent, Mutant-Selective KRASG12D(ON) Inhibitor (GlobeNewswire)
Aug-17-23 04:05PM	Revolution Medicines Announces Publication Describing Molecular Basis of Tri-Complex Inhibitors Targeting Oncogenic RAS(ON) Proteins (GlobeNewswire)
Aug-09-23 02:13PM	Industry Analysts Just Made A Sizeable Upgrade To Their Revolution Medicines, Inc. (NASDAQ:RVMD) Revenue Forecasts (Simply Wall St.)
Aug-08-23 05:50PM	Revolution Medicines, Inc. (RVMD) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
04:05PM	Revolution Medicines Reports Second Quarter 2023 Financial Results and Update on Corporate Progress (GlobeNewswire)
Aug-03-23 04:05PM	Revolution Medicines to Report Financial Results for Second Quarter 2023 After Market Close on August 8, 2023 (GlobeNewswire)
Aug-01-23 02:34PM	EQRx sells to another Alexis Borisy biotech after multiple pivots (American City Business Journals) +20.00%
07:00AM	Revolution Medicines, Inc. to Acquire EQRx, Inc. in All-Stock Transaction to Gain More Than $1 Billion in Additional Capital (GlobeNewswire)
Jul-06-23 09:59AM	Revolution Medicines Insider Ups Holding During Year (Simply Wall St.)
Jun-09-23 08:29AM	We're Not Very Worried About Revolution Medicines' (NASDAQ:RVMD) Cash Burn Rate (Simply Wall St.)
Jun-08-23 04:05PM	Revolution Medicines to Participate in Upcoming Investor Conferences (GlobeNewswire) -7.69%
May-24-23 04:05PM	Revolution Medicines to Participate in TD Cowen 4th Annual Oncology Innovation Summit (GlobeNewswire)
May-13-23 08:19AM	Revolution Medicines, Inc. (NASDAQ:RVMD) Analysts Just Trimmed Their Revenue Forecasts By 25% (Simply Wall St.)
May-10-23 06:10AM	Revolution Medicines First Quarter 2023 Earnings: Beats Expectations (Simply Wall St.)
May-09-23 09:40AM	Q1 2023 Revolution Medicines Inc Earnings Call (Thomson Reuters StreetEvents)
May-08-23 05:25PM	Revolution Medicines, Inc. (RVMD) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:02PM	Revolution Medicines Reports First Quarter 2023 Financial Results and Update on Corporate Progress (GlobeNewswire)
May-03-23 10:00AM	AcelRx Pharmaceuticals (ACRX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release (Zacks)
09:55AM	Wall Street Analysts Think Revolution Medicines, Inc. (RVMD) Could Surge 27.24%: Read This Before Placing a Bet (Zacks)

Revolution Medicines, Inc. is a clinical-stage precision oncology company, which engages in developing novel targeted therapies. It engages in the discovery and development of cancer treatment by pioneering novel combination and monotherapy treatment regimens to maximize the depth and durability of clinical benefit and circumvent adaptive resistance mechanisms for patients which are dependent on the RAS and mTOR pathway. The company was founded by Mark A. Goldsmith, Kevan Shokat, Martin D. Burke, David L. Pompliano and Michael Fischbach in October 2014 and is headquartered in Redwood City, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
GOLDSMITH MARK A	See Remarks	Jun 30 '25	Option Exercise	0.54	37,000	19,980	465,720	Jul 02 04:11 PM
Cislini Jeff	General Counsel	Jun 20 '25	Sale	39.61	1,912	75,736	54,093	Jun 23 04:07 PM
JEFFREY TODD CISLINI	Officer	Jun 20 '25	Proposed Sale	39.93	1,912	76,346		Jun 20 04:23 PM
Horn Margaret A	Chief Operating Officer	Jun 16 '25	Sale	39.83	3,510	139,803	150,675	Jun 18 04:06 PM
GOLDSMITH MARK A	See Remarks	Jun 16 '25	Sale	39.83	13,496	537,546	428,720	Jun 18 04:06 PM
Cislini Jeff	General Counsel	Jun 16 '25	Sale	39.83	1,878	74,801	56,005	Jun 18 04:06 PM
Anders Jack	Chief Financial Officer	Jun 16 '25	Sale	39.83	2,170	86,431	113,314	Jun 18 04:05 PM
Kelsey Stephen Michael	See Remarks	Jun 16 '25	Sale	39.83	4,289	170,831	289,414	Jun 18 04:05 PM
Wei Lin	Chief Medical Officer	Jun 16 '25	Sale	39.83	2,173	86,551	90,499	Jun 18 04:05 PM
Wei Lin	Officer	Jun 16 '25	Proposed Sale	40.79	2,131	86,923		Jun 13 05:25 PM
Kelsey Stephen Michael	Officer	Jun 16 '25	Proposed Sale	40.79	3,732	152,228		Jun 13 05:05 PM
Horn Margaret A	Officer	Jun 16 '25	Proposed Sale	40.79	3,320	135,423		Jun 13 05:03 PM
GOLDSMITH MARK A	Officer	Jun 16 '25	Proposed Sale	40.79	13,235	539,856		Jun 13 05:00 PM
Cislini Jeff	Officer	Jun 16 '25	Proposed Sale	40.79	1,842	75,135		Jun 13 04:58 PM
Anders Jack	Officer	Jun 16 '25	Proposed Sale	40.79	2,127	86,760		Jun 13 04:55 PM
Cislini Jeff	General Counsel	Mar 20 '25	Sale	38.71	2,041	79,008	57,723	Mar 24 04:55 PM
JEFFREY TODD CISLINI	Officer	Mar 20 '25	Proposed Sale	38.75	2,041	79,089		Mar 20 04:32 PM
Cislini Jeff	General Counsel	Mar 17 '25	Sale	39.04	1,458	56,921	59,764	Mar 19 05:43 PM
GOLDSMITH MARK A	See Remarks	Mar 17 '25	Sale	39.04	11,738	458,255	441,564	Mar 19 05:43 PM
Anders Jack	Chief Financial Officer	Mar 17 '25	Sale	39.04	1,864	72,771	115,006	Mar 19 05:42 PM
Horn Margaret A	Chief Operating Officer	Mar 17 '25	Sale	39.04	3,058	119,385	153,533	Mar 19 05:41 PM
Kelsey Stephen Michael	See Remarks	Mar 17 '25	Sale	39.04	3,294	128,599	293,051	Mar 19 05:40 PM
Anders Jack	Officer	Mar 17 '25	Proposed Sale	38.89	2,108	81,980		Mar 14 05:42 PM
Cislini Jeff	Officer	Mar 17 '25	Proposed Sale	38.89	1,650	64,168		Mar 14 05:14 PM
Kelsey Stephen Michael	Officer	Mar 17 '25	Proposed Sale	38.89	3,611	140,432		Mar 14 04:47 PM
Horn Margaret A	Officer	Mar 17 '25	Proposed Sale	38.89	3,406	132,459		Mar 14 04:18 PM
GOLDSMITH MARK A	Officer	Mar 17 '25	Proposed Sale	38.89	11,890	462,402		Mar 14 04:09 PM
Cislini Jeff	General Counsel	Jan 21 '25	Sale	40.50	2,406	97,443	39,222	Jan 22 05:30 PM
JEFFREY TODD CISLINI	Officer	Jan 21 '25	Proposed Sale	40.29	2,406	96,938		Jan 21 04:20 PM
GOLDSMITH MARK A	See Remarks	Dec 18 '24	Option Exercise	0.49	30,846	15,115	355,902	Dec 20 04:50 PM
Horn Margaret A	Chief Operating Officer	Dec 16 '24	Sale	45.40	4,329	196,553	127,991	Dec 18 04:09 PM
GOLDSMITH MARK A	See Remarks	Dec 16 '24	Sale	45.40	11,714	531,860	325,056	Dec 18 04:08 PM
Kelsey Stephen Michael	See Remarks	Dec 16 '24	Sale	45.40	4,663	211,718	259,745	Dec 18 04:07 PM
Cislini Jeff	General Counsel	Dec 16 '24	Sale	45.40	1,599	72,601	41,628	Dec 18 04:07 PM
Anders Jack	Chief Financial Officer	Dec 16 '24	Sale	45.40	2,635	119,639	96,470	Dec 18 04:06 PM
GOLDSMITH MARK A	Officer	Dec 16 '24	Proposed Sale	44.93	11,561	519,436		Dec 16 09:35 PM
Kelsey Stephen Michael	Officer	Dec 16 '24	Proposed Sale	44.93	4,604	206,858		Dec 16 08:42 PM
Cislini Jeff	Officer	Dec 16 '24	Proposed Sale	44.93	1,432	64,340		Dec 16 08:01 PM
Horn Margaret A	Officer	Dec 16 '24	Proposed Sale	44.93	4,271	191,896		Dec 16 07:39 PM
Anders Jack	Officer	Dec 16 '24	Proposed Sale	44.93	2,600	116,818		Dec 16 04:57 PM
Schroeder Thilo	Director	Dec 05 '24	Buy	46.00	1,304,347	59,999,962	2,096,612	Dec 09 04:15 PM
Cislini Jeff	General Counsel	Nov 15 '24	Sale	55.13	2,554	140,811	43,080	Nov 19 04:05 PM
JEFFREY TODD CISLINI	Officer	Nov 15 '24	Proposed Sale	57.37	2,554	146,523		Nov 15 04:44 PM
Kelsey Stephen Michael	See Remarks	Nov 13 '24	Option Exercise	4.09	16,666	68,164	281,074	Nov 15 04:08 PM
Kelsey Stephen Michael	See Remarks	Nov 13 '24	Sale	58.65	16,666	977,509	264,408	Nov 15 04:08 PM
STEPHEN M. KELSEY	Officer	Nov 13 '24	Proposed Sale	59.33	16,666	988,794		Nov 13 04:30 PM
Cislini Jeff	General Counsel	Nov 06 '24	Option Exercise	36.57	6,000	219,420	51,634	Nov 08 04:20 PM
Cislini Jeff	General Counsel	Nov 06 '24	Sale	60.00	6,000	360,000	45,634	Nov 08 04:20 PM
JEFFREY TODD CISLINI	Officer	Nov 06 '24	Proposed Sale	56.75	6,000	340,500		Nov 06 05:07 PM
GOLDSMITH MARK A	See Remarks	Nov 04 '24	Option Exercise	2.58	87,500	226,115	351,070	Nov 05 04:21 PM
GOLDSMITH MARK A	See Remarks	Nov 01 '24	Option Exercise	4.09	9,100	37,219	309,270	Nov 05 04:21 PM
GOLDSMITH MARK A	See Remarks	Nov 04 '24	Sale	55.56	50,900	2,827,821	300,170	Nov 05 04:21 PM
GOLDSMITH MARK A	See Remarks	Nov 01 '24	Sale	55.02	10,000	550,238	20,424	Nov 05 04:21 PM
GOLDSMITH MARK A	See Remarks	Nov 01 '24	Sale	55.02	9,100	500,714	300,170	Nov 05 04:21 PM
Patel Sushil	Director	Oct 31 '24	Option Exercise	24.84	5,000	124,200	24,948	Nov 04 04:05 PM
Patel Sushil	Director	Oct 31 '24	Sale	54.14	5,000	270,714	19,948	Nov 04 04:05 PM
REBECCA EVE GOLDSMITH TR U/A D	Director	Nov 01 '24	Proposed Sale	53.50	5,000	267,500		Nov 01 04:43 PM
J H GOLDSMITH & M A GOLDSMITH	Director	Nov 01 '24	Proposed Sale	53.50	5,000	267,500		Nov 01 04:42 PM
MARK A GOLDSMITH	Director	Nov 01 '24	Proposed Sale	53.50	60,000	3,210,000		Nov 01 04:42 PM
SUSHIL PATEL	Director	Oct 31 '24	Proposed Sale	50.50	5,000	252,500		Oct 31 04:30 PM
Kelsey Stephen Michael	See Remarks	Oct 14 '24	Option Exercise	4.09	16,666	68,164	281,074	Oct 16 04:07 PM
Kelsey Stephen Michael	See Remarks	Oct 14 '24	Sale	49.49	16,666	824,804	264,408	Oct 16 04:07 PM
Horn Margaret A	Chief Operating Officer	Oct 11 '24	Option Exercise	4.09	50,000	204,500	182,320	Oct 15 05:31 PM
Horn Margaret A	Chief Operating Officer	Oct 11 '24	Sale	50.34	50,000	2,517,055	132,320	Oct 15 05:31 PM
GOLDSMITH MARK A	See Remarks	Oct 11 '24	Option Exercise	4.09	30,000	122,700	330,170	Oct 15 05:30 PM
GOLDSMITH MARK A	See Remarks	Oct 11 '24	Sale	50.36	30,000	1,510,773	300,170	Oct 15 05:30 PM
Anders Jack	Chief Financial Officer	Oct 11 '24	Option Exercise	2.68	10,000	26,800	108,932	Oct 15 05:30 PM
Anders Jack	Chief Financial Officer	Oct 11 '24	Sale	50.30	10,000	502,979	98,932	Oct 15 05:30 PM
Cislini Jeff	General Counsel	Oct 11 '24	Option Exercise	36.57	6,000	219,420	51,634	Oct 15 05:29 PM
Cislini Jeff	General Counsel	Oct 11 '24	Sale	50.17	6,000	301,027	45,634	Oct 15 05:29 PM
STEPHEN M. KELSEY	Officer	Oct 14 '24	Proposed Sale	50.48	16,666	841,300		Oct 15 08:03 AM
MARK A GOLDSMITH	Director	Oct 11 '24	Proposed Sale	49.50	30,000	1,485,000		Oct 11 04:22 PM
JEFFREY TODD CISLINI	Officer	Oct 11 '24	Proposed Sale	49.50	6,000	297,000		Oct 11 04:21 PM
JACK LEE ANDERS	Officer	Oct 11 '24	Proposed Sale	49.50	10,000	495,000		Oct 11 04:21 PM
MARGARET A HORN	Officer	Oct 11 '24	Proposed Sale	49.50	50,000	2,475,000		Oct 11 04:21 PM
Weber Barbara	Director	Oct 08 '24	Sale	48.02	5,200	249,716	13,065	Oct 10 04:16 PM
BARBARA L WEBER	Director	Oct 08 '24	Proposed Sale	47.34	5,200	246,168		Oct 08 04:23 PM
GOLDSMITH MARK A	See Remarks	Oct 01 '24	Option Exercise	4.09	10,000	40,900	310,170	Oct 03 04:33 PM
GOLDSMITH MARK A	See Remarks	Oct 01 '24	Sale	44.93	10,000	449,322	300,170	Oct 03 04:33 PM
MARK A GOLDSMITH	Director	Oct 01 '24	Proposed Sale	45.35	10,000	453,500		Oct 01 04:33 PM
Anders Jack	Chief Financial Officer	Sep 16 '24	Sale	44.19	2,244	99,152	98,932	Sep 18 04:18 PM
GOLDSMITH MARK A	See Remarks	Sep 16 '24	Sale	44.19	11,715	517,631	300,170	Sep 18 04:18 PM
Horn Margaret A	Chief Operating Officer	Sep 16 '24	Sale	44.19	4,331	191,367	132,320	Sep 18 04:17 PM
Kelsey Stephen Michael	See Remarks	Sep 16 '24	Sale	44.19	4,665	206,124	264,408	Sep 18 04:17 PM
Cislini Jeff	General Counsel	Sep 16 '24	Sale	44.19	1,454	64,245	45,634	Sep 18 04:16 PM
Anders Jack	Officer	Sep 16 '24	Proposed Sale	42.12	1,832	77,164		Sep 16 07:06 PM
Kelsey Stephen Michael	Officer	Sep 16 '24	Proposed Sale	42.12	4,601	193,794		Sep 16 06:41 PM
Horn Margaret A	Officer	Sep 16 '24	Proposed Sale	42.12	4,271	179,895		Sep 16 06:22 PM
Cislini Jeff	Officer	Sep 16 '24	Proposed Sale	42.12	1,433	60,358		Sep 16 05:37 PM
Anders Jack	Officer	Sep 16 '24	Proposed Sale	42.12	1,832	77,164		Sep 16 05:24 PM
GOLDSMITH MARK A	Officer	Sep 16 '24	Proposed Sale	42.12	11,561	486,949		Sep 16 05:15 PM
Kelsey Stephen Michael	See Remarks	Sep 13 '24	Option Exercise	4.09	16,667	68,168	285,740	Sep 16 04:05 PM
Kelsey Stephen Michael	See Remarks	Sep 13 '24	Sale	43.32	16,667	722,087	269,073	Sep 16 04:05 PM
STEPHEN M. KELSEY	Officer	Sep 13 '24	Proposed Sale	41.97	16,667	699,514		Sep 13 04:23 PM
BARBARA L WEBER	Officer	Aug 21 '24	Proposed Sale	44.83	1,808	81,053		Aug 21 04:14 PM
Kelsey Stephen Michael	See Remarks	Aug 13 '24	Option Exercise	4.09	16,667	68,168	285,740	Aug 15 04:48 PM
Kelsey Stephen Michael	See Remarks	Aug 13 '24	Sale	42.98	16,667	716,389	269,073	Aug 15 04:48 PM
STEPHEN M. KELSEY	Officer	Aug 13 '24	Proposed Sale	42.98	16,667	716,348		Aug 13 04:25 PM
GOLDSMITH MARK A	See Remarks	Aug 01 '24	Option Exercise	4.09	10,000	40,900	321,885	Aug 02 05:35 PM
GOLDSMITH MARK A	See Remarks	Aug 01 '24	Sale	45.88	10,000	458,827	311,885	Aug 02 05:35 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

RVMD

Revolution Medicines Inc

Upgrade your FINVIZ experience